Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.95 SEK | +6.50% | +5.56% | +7.95% |
27/02 | Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Sales 2021 | - | Sales 2022 | - | Capitalization | 21.03M 230M 1.75B |
---|---|---|---|---|---|
Net income 2021 | -31M -338M -2.59B | Net income 2022 | -13M -142M -1.08B | EV / Sales 2021 | - |
Net cash position 2021 | 16.42M 179M 1.37B | Net cash position 2022 | 13.58M 148M 1.13B | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.15
x | P/E ratio 2022 |
-1.31
x | Employees | 1 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.98% |
1 day | +6.50% | ||
1 week | +5.56% | ||
Current month | +5.56% | ||
1 month | -3.06% | ||
3 months | -20.17% | ||
6 months | +27.01% | ||
Current year | +7.95% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Nordkild
CEO | Chief Executive Officer | 69 | 01/16/01 |
Director of Finance/CFO | 69 | 01/17/01 | |
Public Communications Contact | 62 | 01/11/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul de Potocki
CHM | Chairman | 62 | 01/18/01 |
Public Communications Contact | 62 | 01/11/01 | |
Marianne Kock
BRD | Director/Board Member | 69 | 01/18/01 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 0.95 | +6.50% | 49 |
26/24/26 | 0.892 | -6.11% | 3,318 |
25/24/25 | 0.95 | 0.00% | 22,785 |
24/24/24 | 0.95 | +1.50% | 1,768 |
23/24/23 | 0.936 | +4.00% | 22,999 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 02:52 pm IST
More quotes1st Jan change | Capi. | |
---|---|---|
+7.95% | 1.84M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.67% | 22.15B | |
-17.37% | 21.02B | |
-9.05% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ASAP Stock